MTOR and cancer: Studies have reported that combination therapy of SAR405 with the mTOR inhibitor everolimus promotes the inhibition of cancer progression in renal tumour cell lines, hence indicating the efficacy of SAR405 as an anticancer drug that targets the regulation of autophagy [116].